nateglinide

[nah-teg´lĭ-nīd] an antidiabetic agent that lowers blood glucose concentrations by stimulating the release of insulin from pancreatic islet beta cells; administered orally in the treatment of type 2 diabetes mellitus, either alone or in combination with metformin.

nateglinide

Starlix

Pharmacologic class: Amino acid derivative

Therapeutic class: Hypoglycemic

Pregnancy risk category C

Action

Decreases blood glucose level by stimulating insulin secretion from pancreatic beta cells; interacts with calcium and potassium channels in pancreas

Availability

Tablets: 60 mg, 120 mg

Indications and dosages

➣ To decrease glucose levels in type 2 (non-insulin-dependent) diabetes mellitus not adequately controlled by diet and exercise

Adults: 120 mg P.O. t.i.d. up to 30 minutes before meals, or 60 mg P.O. t.i.d. if patient is near glycosylated hemoglobin (HbA1c) goal

Contraindications

• Hypersensitivity to drug or its components

• Diabetic ketoacidosis

• Type 1 (insulin-dependent) diabetes mellitus

Precautions

Use cautiously in:

• renal or hepatic impairment, adrenal or pituitary insufficiency

• elderly or malnourished patients

• pregnant or breastfeeding patients.

Administration

• Give 30 minutes before meals. If meal is missed, don't give dose.

• Know that drug may be given alone or with metformin.

Adverse reactions

CNS: dizziness

GI: diarrhea

Metabolic: hypoglycemia

Musculoskeletal: back pain, joint pain

Respiratory: upper respiratory tract infection, bronchitis, coughing

Other: flulike symptoms, trauma

Interactions

Drug-drug. Beta-adrenergic blockers, MAO inhibitors, nonsteroidal antiinflammatory drugs, salicylates: increased hypoglycemic effect

Corticosteroids, sympathomimetics, thiazides, thyroid products: reduced hypoglycemic effect

Drug-diagnostic tests. Glucose: decreased level

Patient monitoring

• Monitor blood glucose and HbA1c levels.

• Assess pulmonary status for bronchitis, upper respiratory infection, and flulike signs and symptoms.

• Monitor musculoskeletal status. Check for back pain and arthropathy.

• Note GI complaints, and identify nutritional deficiencies.

Patient teaching

• Instruct patient to take dose up to 30 minutes before each main meal.

• Advise patient not to skip a meal. If he does, tell him to also skip accompanying nateglinide dose, to prevent hypoglycemia.

• Teach patient how to monitor blood and urine for glucose and ketones, as prescribed.

• Instruct patient to report adverse CNS effects and signs and symptoms of respiratory infection.

• Caution patient to avoid driving and other hazardous activities until he knows how drug affects sensation and balance.

• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above.

nateglinide

(nə-tĕg′lĭ-nīd′)n. An oral hypoglycemic drug, C₁₉H₂₇NO₃, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes.

单词	nateglinide
释义	nateglinide na·teg·li·nide N5030175 (nə-tĕg′lĭ-nīd′)n. An oral hypoglycemic drug, C₁₉H₂₇NO₃, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes. [nate-, origin unknown + -glinide, antidiabetic drug suff.; see repaglinide.] nateglinide nateglinide [nah-teg´lĭ-nīd] an antidiabetic agent that lowers blood glucose concentrations by stimulating the release of insulin from pancreatic islet beta cells; administered orally in the treatment of type 2 diabetes mellitus, either alone or in combination with metformin. nateglinide Starlix *Pharmacologic class:* Amino acid derivative *Therapeutic class:* Hypoglycemic *Pregnancy risk category C* Action Decreases blood glucose level by stimulating insulin secretion from pancreatic beta cells; interacts with calcium and potassium channels in pancreas Availability Tablets: 60 mg, 120 mg Indications and dosages ➣ To decrease glucose levels in type 2 (non-insulin-dependent) diabetes mellitus not adequately controlled by diet and exercise Adults: 120 mg P.O. t.i.d. up to 30 minutes before meals, or 60 mg P.O. t.i.d. if patient is near glycosylated hemoglobin (HbA1c) goal Contraindications • Hypersensitivity to drug or its components • Diabetic ketoacidosis • Type 1 (insulin-dependent) diabetes mellitus Precautions Use cautiously in: • renal or hepatic impairment, adrenal or pituitary insufficiency • elderly or malnourished patients • pregnant or breastfeeding patients. Administration • Give 30 minutes before meals. If meal is missed, don't give dose. • Know that drug may be given alone or with metformin. Adverse reactions CNS: dizziness GI: diarrhea Metabolic: hypoglycemia Musculoskeletal: back pain, joint pain Respiratory: upper respiratory tract infection, bronchitis, coughing Other: flulike symptoms, trauma Interactions Drug-drug. Beta-adrenergic blockers, MAO inhibitors, nonsteroidal antiinflammatory drugs, salicylates: increased hypoglycemic effect Corticosteroids, sympathomimetics, thiazides, thyroid products: reduced hypoglycemic effect Drug-diagnostic tests. Glucose: decreased level Patient monitoring • Monitor blood glucose and HbA1c levels. • Assess pulmonary status for bronchitis, upper respiratory infection, and flulike signs and symptoms. • Monitor musculoskeletal status. Check for back pain and arthropathy. • Note GI complaints, and identify nutritional deficiencies. Patient teaching • Instruct patient to take dose up to 30 minutes before each main meal. • Advise patient not to skip a meal. If he does, tell him to also skip accompanying nateglinide dose, to prevent hypoglycemia. • Teach patient how to monitor blood and urine for glucose and ketones, as prescribed. • Instruct patient to report adverse CNS effects and signs and symptoms of respiratory infection. • Caution patient to avoid driving and other hazardous activities until he knows how drug affects sensation and balance. • As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the drugs and tests mentioned above. nateglinide (nə-tĕg′lĭ-nīd′)n. An oral hypoglycemic drug, C₁₉H₂₇NO₃, that stimulates the release of insulin from the pancreas and is used to treat type 2 diabetes.
随便看	exostectomy exostes exostome exostosectomy exostoses exostoses, multiple cartilaginous exostoses, multiple hereditary exostoses, multiple, type 1 exostoses, multiple, type 2 exostosis exostosis bursata exostosis cartilaginea exosurf exoteric exoterical exoterically exoteric bacterium exotericism exotericly exoterics exoterism exotery exotheca exothecium exotherm

nateglinide

na·teg·li·nide

nateglinide

nateglinide

nateglinide

Action

Availability

Indications and dosages

Contraindications

Precautions

Administration

Adverse reactions

Interactions

Patient monitoring

Patient teaching

nateglinide